XyloCor finds new backing to push regenerative heart disease gene therapy deeper into the clinic
XyloCor Therapeutics is one step closer to accomplishing the tough task of delivering gene therapies straight into the heart for coronary artery disease.
Three years …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.